BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference

CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE#BeiGene–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company,today announced that the Company will participate in Cowen’s 43^rd Annual Healthcare Conference on Monday, March 6^th, 2023 with a fireside chat at 11:10 am ET.

Live webcasts of these events can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com and archived replays will be available for 90 days following the events.

About BeiGene

BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 9,000 colleagues spans five continents, with administrative offices in Cambridge, U.S., & Basel, Switzerland & Beijing, China. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneGlobal.

Forward-Looking Statements

This fireside chat contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s plans, commitments, aspirations and goals related to BeiGene’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q or annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the SEC. All information in this fireside chat is as of the date presented, and BeiGene undertakes no duty to update such information unless required by law.

Contacts

Investor:
Kevin Mannix

+1 240-410-0129

ir@beigene.com

Media:
Kyle Blankenship

+1 667- 351-5176

media@beigene.com